3D Systems Announces Expansion Plans to Address Rising Demand for New Healthcare and Industrial Applications
- Company adding 50,000 square feet of facility space, additional application expertise, and new additive manufacturing technologies in Denver, Colorado
- Increased resources will address increasing demand for patient-specific healthcare and highly-regulated industrial applications utilizing the most advanced polymer and metal additive
ROCK HILL, S.C., May 04, 2021 (GLOBE NEWSWIRE) -- 3D Systems (NYSE:DDD) today announced it will increase its presence in Denver, Colorado to support its fast-growing healthcare solutions business, and expand industrial application development capabilities for its Application Innovation Group (AIG). This activity is a continuation of the investment phase of the company’s plan to focus on its strategic purpose as the leaders in enabling additive manufacturing solutions for applications in growing markets that demand high-reliability products.
Patient-specific Solutions Transform How Healthcare is Delivered
For more than a decade, 3D Systems has delivered a portfolio of industry-leading healthcare solutions, including patient-specific surgical instruments and implants manufactured at its FDA-registered and ISO 13485-certified location in Denver. The company has supported customers of all sizes, ranging from industry leaders to innovative startups, in developing a diverse portfolio of groundbreaking precision healthcare applications and new medical technology. 3D Systems has manufactured more than two million medical device implants, collaborated with surgeons to plan and guide more than 140,000 patient-specific procedures, and supported 100+ CE-marked and FDA-cleared products. Through this next phase of investment, the company will be able to accelerate time-to-market, expand its offerings, and better support the needs of its rapidly growing customer base. This positions 3D Systems to continue its strong growth trajectory for patient-specific craniomaxillofacial applications through expanded production capacity and ongoing product innovations. It will also enable the company to aggressively increase its participation in the larger patient-specific orthopedics market through the development and deployment of new joint replacement solutions.